Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 110, Issue 3, Pages 359-368Publisher
SPRINGER
DOI: 10.1007/s11060-012-0981-6
Keywords
Glioblastoma multiforme (GBM); Signal transducer and activator of transcription 3 (STAT3); Small molecule inhibitor; Immunotherapy
Categories
Funding
- Johns Hopkins School of Medicine Dean's Year of Research Program
- W. W. Smith Charitable Trust Medical Research Grant
- Association for Academic Surgery Joel J. Roslyn Faculty Research Award
- Neurosurgery Research and Education Foundation (NREF)
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) modulates the immune system to engance its malignant potential. Signal transducer and activator of transcription 3 (STAT3) activation is a regulatory node in modulating the immune microenvironment in several human tumors, including GBM. To investigate whether STAT3 inhibition might enhance anti-tumor responses, we inhibited STAT3 signaling using small interfering RNA against STAT3. We tested the human GBM cell lines U87, U251, and HS683, which are known to constitutively express high levels of phospho-STAT3. STAT3 inhibition resulted in enhanced expression of several pro-inflammatory cytokines and chemokines and supernatants from STAT3-silenced human GBM cell lines increased lipopolysaccharide-induced dendritic cell activation in vitro. We obtained comparable results when STAT3 activity was suppressed with specific small molecule inhibitors. Our results support the hypothesis that activated STAT3 contributes to the immunosuppressive microenvironment in GBM and support previous studies implicating STAT3 as a potential target for immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available